Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
8 stopped studies mapped to Angiosarcoma and descendants · 100% state a reason
Over the 8 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05026736 | Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma,… | Phase 2 | terminated | Aug 30, 2021 | M.D. Anderson Cancer Center | PI request, \<75% participation | Other (stated, no rule matched) |
| NCT05799612 | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous… | Phase 1 | withdrawn | Apr 5, 2023 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | Phase 2 | terminated | Apr 19, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor Terminated Funding | Funding |
| NCT02212015 | Evaluation of Votrient in Angiosarcoma(EVA) | Phase 2 | terminated | Aug 8, 2014 | Heidelberg University | Due to interim analysis' results and definitions fixed in protocol | Efficacy / futility |
| NCT04607200 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | Phase 2 | withdrawn | Oct 29, 2020 | Agenus Inc. | Strategic business decision | Sponsor / business decision |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Phase 2 | withdrawn | Nov 11, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With… | Phase 2 | withdrawn | May 28, 2021 | Brown University | IND withdrawn | Other (stated, no rule matched) |
| NCT01055028 | Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable… | Phase 2 | terminated | Jan 25, 2010 | Stanford University | Poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials